CASE STUDIES

How the Head of Global Market Access for an oral oncolytic was able to increase revenue potential by thinking outside the U.S.

How a thorough assessment of a manufacturer's patient services department helped optimize a Hybrid HUB for future success.

How a U.S. biotech company established a global supply chain for a cell therapy with complicated and unique characteristics.

How a young biotech company with only a handful of employees was fully contracted and on schedule to implement in advance of launch.

How a mid-sized manufacturer's commercial operations team increased efficiency and drove future scalability with a comprehensive third-party assessment.

How a growing manufacturer identified $2.7M in savings with a thorough analysis of their existing Distribution Service Agreements.

How one manufacturer is now leveraging more accurate, meaningful, and actionable data to make strategic decisions.

How a young biotech company successfully integrated data across seven external vendors

How a large manufacturer accelerated time to therapy with a full suite of digitalized services.

How a large manufacturer was able to leverage benchmark fee ranges to better negotiate distribution agreements.

How a pharmaceutical company determined the best distribution strategy for a challenging oncology product.

How a small pharmaceutical manufacturer realized significant savings following a review of distribution partner contracts.

How an US-based cell therapy company overcame a tight timeline to gain insights from key stakeholders across 5 European markets.

How a pharmaceutical company revamped an old, inefficient HUB model to save 1/4 of their annual budget and increase sales by 1/3.

How a manufacturer successfully prepared for a hybrid HUB launch by temporarily extending their team's expertise.

How one manufacturer decreased time to fill by 2 months and boosted incremental revenue by $15M.

How a manufacturer was able to align multiple stakeholder needs to select the best Limited Distribution Specialty Pharmacy for their rare disease product

How a manufacturer was able to rescue 25% of pending referrals in less than 2 months, amounting to an initial $11M revenue boost

How a new manufacturer successfully relaunched a stagnant product line with limited trade and distribution staff and experience.

How a biotech company was able to quickly understand the retinal landscape to build a commercial distribution strategy for their first launch.

How a biotech company was able to identify and address potential future commercial operational complexities early in clinical development.

How a manufacturer was able to identify and correct significant site of care issues ahead of launch.

How a small biotech successfully managed escalations around launch without adding staff.

How a large, global manufacturer successfully managed a patient support launch strategy in a crowded specialty market on time and under budget.

How an established patient support program was able to identify and overcome design barriers to stimulate access.

How a large manufacturer was able to identify additional access drivers for a PSP model design ahead of launch, while securing essential internal stakeholder support.

How implementing a Quality Management System helped a Brand team improve benefit verification accuracy by 4.8% in 2 months.

How one manufacturer implemented several patient support initiatives over a 6-month period by bringing on temporary skilled staffing support.

How a new oncology therapy used a well-designed SP network to overcome AE concerns and exceed sales expectations.

How one manufacturer leveraged smart contracting to find innovation and flexibility alongside efficiencies and overall savings.

How a manufacturer selected a 3PL partner best suited to the unique needs of their product and immediately began preparing for launch.

How a mid-sized manufacturer met the complex needs of their pediatric product's stakeholders by placing support services at the SP, instead of the HUB

How a large manufacturer successfully transitioned an internal, 5-product HUB to a third-party vendor on schedule.

How a cell therapy manufacturer was able to avoid COVID-19 disruptions to their distribution model.

How a large manufacturer methodically assessed and optimized a free goods program to avoid access disruptions.